Cube Pharmaceuticals announced that the 12th batch of nationally organized drugs was selected from the company's products for centralized volume procurement. Doxazosin mesylate sustained-release tablets had sales revenue of 103 million yuan in 2025, accounting for 6.66% of the company's 2025 revenue; sales revenue for the first quarter of 2026 was 253.194 million yuan, accounting for 7.09% of the company's revenue for the first quarter of 2026. Mesartan potassium tablets were approved for marketing on May 19, 2026, and no sales revenue has been generated. The selection results will be implemented within this year, and the procurement cycle starts from the date of execution of the selected results to December 31, 2029.

Cube Pharmaceuticals announced that the 12th batch of nationally organized drugs was selected from the company's products for centralized volume procurement. Doxazosin mesylate sustained-release tablets had sales revenue of 103 million yuan in 2025, accounting for 6.66% of the company's 2025 revenue; sales revenue for the first quarter of 2026 was 253.194 million yuan, accounting for 7.09% of the company's revenue for the first quarter of 2026. Mesartan potassium tablets were approved for marketing on May 19, 2026, and no sales revenue has been generated. The selection results will be implemented within this year, and the procurement cycle starts from the date of execution of the selected results to December 31, 2029.